

05-03-2000

FORM PTO-1595

(Rev. 6-93)

OMB No. 0651-0011 (exp. 4/94)

M&G-10880 3US01, 10880 4US01, 10880 5US01, 10880 6US01

F



101344088

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

To the Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

U.S. Bioscience, Inc.

2. Name and address of receiving party(ies):

MedImmune Oncology, Inc.
35 W. Watkins Mill Road
Gaithersburg, MD 20878
USAAdditional name(s) of conveying party(ies) attached? ☐ Yes ☒ NoAdditional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☐ Assignment ☐ Merger
☒ Security Agreement ☒ Change of Name
☐ Other:

Execution Date: February 10, 2000

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

B. Patent No.(s)

5804571, 5292497, 4957481, 4956459

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Douglas P. Mueller
Address: MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903

6. Total number of applications and patents involved: 4

7. Total fee (37 CFR 3.41): \$ 160.00

- ☒ Enclosed
☐ Authorized to be charged to deposit account

8. Please charge any additional fees or credit any overpayments to our Deposit account number: 13-2725

Statement and signature:

DO NOT USE THIS SPACE

9. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Douglas P. Mueller

Name of Person Signing

Signature

April 3, 2000

Date

Total number of pages including attachments and document:

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks
Box Assignments
Washington, D.C. 20231

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner of Patents and Trademarks, Box Assignments, Washington, D.C. 20231 on April 3, 2000.

Name: Douglas P. Mueller

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of information systems, PK2-1000C, Washington, D.C. 20231 and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

PATENT
REEL: 010742 FRAME: 0074

State of Delaware
Office of the Secretary of State

PAGE 1

I, EDWARD J. FREEL, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "U.S. BIOSCIENCE, INC.", CHANGING ITS NAME FROM "U.S. BIOSCIENCE, INC." TO "MEDIMMUNE ONCOLOGY, INC.", FILED IN THIS OFFICE ON THE TENTH DAY OF FEBRUARY, A.D. 2000, AT 9 O'CLOCK A.M.



2125713 8100

001070291

A handwritten signature in cursive script, reading "Edward J. Freel", is written over a horizontal line.

Edward J. Freel, Secretary of State

0253164

AUTHENTICATION:

DATE: 02-11-00

PATENT
REEL: 010742 FRAME: 0075

U.S. BIOSCIENCE, INC.

**CERTIFICATE OF AMENDMENT TO
RESTATED CERTIFICATE OF INCORPORATION**

U.S. BIOSCIENCE, INC., a corporation organized and existing under the laws of the State of Delaware (the "Corporation"), hereby certifies as follows:

1. The Board of Directors of the Corporation, acting by the Written Consent of its Sole Director, duly adopted, pursuant to Section 242 of the General Corporation Law of the State of Delaware (the "GCL"), resolutions setting forth this proposed Amendment to the Restated Certificate of Incorporation of said Corporation and declaring said Amendment to be advisable and directing that such Amendment be presented to the sole stockholder of the Corporation for consideration and approval;

2. The stockholder of the Corporation, acting by the written consent of its Sole Stockholder, approved and adopted this proposed Amendment to the Restated Certificate of Incorporation of said Corporation in accordance with Section 242 of the GCL;

3. Article 1 of the Restated Certificate of Incorporation of the Corporation, dated November 23, 1999, is hereby amended to read in full as follows:

"The name of the Corporation is MedImmune Oncology, Inc."

IN WITNESS WHEREOF, U.S. BIOSCIENCE, INC. has caused this Certificate to be signed by Wayne T. Hockmeyer, Ph.D., Chairman, Chief Executive Officer and President, this 10th day of February, 2000.

U.S. BIOSCIENCE, INC.

By


Wayne T. Hockmeyer, Ph.D.

Chairman, Chief Executive Officer and
President